NCT00624611

Brief Summary

When a child undergoes heart surgery, a heart lung machine is used to keep blood flowing while the child's own heart is stopped. After surgery, a significant amount of the child's own blood is left in this machine. In the case of small children, the relative amount of blood potentially lost to the child in this way is very large. In older children, and those who have undergone less complicated surgery, this blood can all returned to the child. Giving the child back his or her own blood makes is less likely that the child will need a transfusion of donated blood. However, in younger children, or in children who have undergone more complicated surgery, most or all of this blood is thrown away. This is because of worry that returning this blood may cause bleeding, and excessive bleeding is one of the most feared complications of heart surgery. This project will explore a method whereby the red blood cells left in the heart lung machine can be returned to children without increasing the risk of bleeding. It will also carefully examine the exact causes of higher bleeding risk in children getting their own blood back so that in the future, all children can have their own blood returned at the end of surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
9

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Feb 2008

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2008

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

February 13, 2008

Completed
14 days until next milestone

First Posted

Study publicly available on registry

February 27, 2008

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2010

Completed
Last Updated

April 14, 2011

Status Verified

April 1, 2011

Enrollment Period

2.5 years

First QC Date

February 13, 2008

Last Update Submit

April 12, 2011

Conditions

Keywords

CPBred blood cell washing

Outcome Measures

Primary Outcomes (1)

  • Total perioperative blood loss

    During surgery

Secondary Outcomes (1)

  • Components of the hemostatic profile will be compared between groups as secondary outcome variables

    24 hours

Study Arms (2)

1

ACTIVE COMPARATOR

Residual pump blood management post aortic cannula removal

Procedure: Residual pump blood management post aortic cannula removal

2

EXPERIMENTAL

Residual pump blood management post aortic cannula removal

Procedure: Residual pump blood management post aortic cannula removal

Interventions

Residual pump blood will be maximally hemoconcentrated by further ultrafiltation within the CPB machine. Resulting hematocrit will be approximately 0.4. The total residual pump blood volume, approximately 300ml, will be reinfused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Additional protamine sulfate will be given every 30 minutes during the infusion, .03 mg/ml of residual pump blood. Procedures in this group do not deviate from current standard practice.

1

Eligibility Criteria

Age2 Years - 10 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children between 15 and 30 kg undergoing cardiac surgery requiring cardiopulmonary bypass at British Columbia's Children's Hospital.
  • All children will be between 2 and 10 years of age.
  • Surgery will only involve single atriotomy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

BC Children's Hospital

Vancouver, British Columbia, V6H 3V4, Canada

Location

Study Officials

  • Norbert Froese, MD

    University of British Columbia

    PRINCIPAL INVESTIGATOR
  • John Wu

    University of British Columbia

    STUDY DIRECTOR
  • Jacques LeBlanc

    University of British Columbia

    STUDY DIRECTOR
  • Andrew Campbell

    University of British Columbia

    STUDY DIRECTOR
  • Doug Salt

    University of British Columbia

    STUDY DIRECTOR
  • Pascal Lavoie

    University of British Columbia

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

February 13, 2008

First Posted

February 27, 2008

Study Start

February 1, 2008

Primary Completion

August 1, 2010

Study Completion

August 1, 2010

Last Updated

April 14, 2011

Record last verified: 2011-04

Locations